FDA.reportPublic FDA data

1.2 ML somatrogon-ghla 20 MG/ML Pen Injector

RxCUI
2644517
RxNorm name
1.2 ML somatrogon-ghla 20 MG/ML Pen Injector
Display name
1.2 ML somatrogon-ghla 20 MG/ML Pen Injector
Full name
1.2 ML somatrogon-ghla 20 MG/ML Pen Injector
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:38:46

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761184Ngenlasomatrogon-ghla351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NgenlaSOMATROGON-GHLAPfizer Laboratories Div Pfizer Inc06dce529-b741-4a1b-8842-3ad77be6e3082026-05-07Warnings, Adverse reactionsExact identifier
rxcui: 2644517

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
06dce529-b741-4a1b-8842-3ad77be6e3081.2 ML somatrogon-ghla 20 MG/ML Pen InjectorSCD12These highlights do not include all the information needed to use NGENLA safely and effectively. See full prescribing information for NGENLA. NGENLA (somatrogon-ghla) injection, for subcutaneous use Initial U.S. Approval: 202320260507
06dce529-b741-4a1b-8842-3ad77be6e308somatrogon-ghla 24 MG in 1.2 ML Pen InjectorPSN12These highlights do not include all the information needed to use NGENLA safely and effectively. See full prescribing information for NGENLA. NGENLA (somatrogon-ghla) injection, for subcutaneous use Initial U.S. Approval: 202320260507
06dce529-b741-4a1b-8842-3ad77be6e308somatrogon-ghla 20 MG/ML per 1.2 ML Pen InjectorSY12These highlights do not include all the information needed to use NGENLA safely and effectively. See full prescribing information for NGENLA. NGENLA (somatrogon-ghla) injection, for subcutaneous use Initial U.S. Approval: 202320260507
06dce529-b741-4a1b-8842-3ad77be6e308somatrogon-ghla 24 MG per 1.2 ML Pen InjectorSY12These highlights do not include all the information needed to use NGENLA safely and effectively. See full prescribing information for NGENLA. NGENLA (somatrogon-ghla) injection, for subcutaneous use Initial U.S. Approval: 202320260507